MK-2640
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $134,523 | 3 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $134,523 | 3 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A two part study Part I and Part II rising dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of MK-2640 in healthy subjects Part I and evaluation of safety, pharmacokinetics and pharmacodynamics of MK-2640 in subjects with type 1 diabetes mellitus Part II. | Merck Sharp & Dohme Corporation | $134,523 | 0 |
Top Doctors Receiving Payments for MK-2640
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Chula Vista, CA | $134,523 | 3 |
Manufacturing Companies
- Merck Sharp & Dohme Corporation $134,523
Product Information
- Type Biological
- Total Payments $134,523
- Total Doctors 0
- Transactions 3
About MK-2640
MK-2640 is a biological associated with $134,523 in payments to 0 healthcare providers, recorded across 3 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2017. In 2017, $134,523 was paid across 3 transactions to 0 doctors.
The most common payment nature for MK-2640 is "Unspecified" ($134,523, 100.0% of total).
MK-2640 is associated with 1 research study, including "A two part study Part I and Part II rising dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of MK-2640 in healthy subjects Part I and evaluation of safety, pharmacokinetics and pharmacodynamics of MK-2640 in subjects with type 1 diabetes mellitus Part II." ($134,523).